![PDF) Orexin in the anxiety spectrum: association of a HCRTR1 polymorphism with panic disorder/agoraphobia, CBT treatment response and fear-related intermediate phenotypes PDF) Orexin in the anxiety spectrum: association of a HCRTR1 polymorphism with panic disorder/agoraphobia, CBT treatment response and fear-related intermediate phenotypes](https://i1.rgstatic.net/publication/330860610_Orexin_in_the_anxiety_spectrum_association_of_a_HCRTR1_polymorphism_with_panic_disorderagoraphobia_CBT_treatment_response_and_fear-related_intermediate_phenotypes/links/5fb393e6299bf10c36862709/largepreview.png)
PDF) Orexin in the anxiety spectrum: association of a HCRTR1 polymorphism with panic disorder/agoraphobia, CBT treatment response and fear-related intermediate phenotypes
![Global burden of 369 diseases and injuries in 204 countries and territories, 1990–2019: a systematic analysis for the Global Burden of Disease Study 2019 - The Lancet Global burden of 369 diseases and injuries in 204 countries and territories, 1990–2019: a systematic analysis for the Global Burden of Disease Study 2019 - The Lancet](https://els-jbs-prod-cdn.jbs.elsevierhealth.com/cms/attachment/574cfded-2c30-425f-9f42-6c7ea066cb85/gr2a_lrg.jpg)
Global burden of 369 diseases and injuries in 204 countries and territories, 1990–2019: a systematic analysis for the Global Burden of Disease Study 2019 - The Lancet
![Efficacy of molecularly targeted agents given in the randomised trial SHIVA01 according to the ESMO Scale for Clinical Actionability of molecular Targets - European Journal of Cancer Efficacy of molecularly targeted agents given in the randomised trial SHIVA01 according to the ESMO Scale for Clinical Actionability of molecular Targets - European Journal of Cancer](https://els-jbs-prod-cdn.jbs.elsevierhealth.com/cms/attachment/3e80ead5-6080-4962-bf3a-637d2737cffd/gr1_lrg.jpg)